ClinicalTrials.gg
RecruitingNCT05902923Updated May 8, 2024

Investigating the Safety and Clinical Performance of Eight iVascular Devices for Endovascular Intervention in Renal, Iliac or Femoral Arteries

An observational study in Artery Disease, sponsored by iVascular S.L.U.. Recruiting at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by iVascular S.L.U. · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
209
Ages
18 Years and older
Sex
All
01

Study summary

The rationale of this study is to confirm and support the clinical safety and performance of any of these products in a real-world population of 209 patients who underwent an endovascular intervention within standard-of-care of the iliacofemoral artery and renal artery, using at least one of the investigational products from iVascular.

02

Conditions studied

  • Artery Disease
03

In context

Lead sponsor

iVascular S.L.U. is the lead sponsor of 14 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Every patient who is eligible for treatment with any of the following devices, can be considered to be included in the study:

the Oceanus 18 Balloon Dilatation Catheter and/or the Oceanus 35 Balloon Dilatation Catheter and/or the Luminor 18 Drug Coated Balloon and/or the Luminor 35 Drug Coated Balloon and/or the Restorer Peripheral Stent System and/or the iVolution pro Peripheral Self-Expanding Stent System and/or the iCover Covered Peripheral Stent System and/or the Sergeant Peripheral Support Catheter

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Corresponding to the CE-mark indications/ and according to the IFU of the device.
  • Patient is >18 years old.
  • Patient understands the nature of the procedure and provides written prior to enrollment in the study.
  • Target lesion(s) is/are located in renal, iliac or femoral arteries.
  • Patient is eligible for treatment with the Oceanus 18 Balloon Dilatation Catheter and/or the Oceanus 35 Balloon Dilatation Catheter and/or the Luminor 18 Drug Coated Balloon and/or the Luminor 35 Drug Coated Balloon and/or the Restorer Peripheral Stent System and/or the iVolution pro Peripheral Self-Expanding Stent System and/or the iCover Covered Peripheral Stent System and/or the Sergeant Peripheral Support Catheter as described in IFU for each device.

Exclusion criteria

Exclusion Criteria:

  • Anatomy or size of vessels that will not allow appropriate usage of the devices, following IFU of the investigational devices.
  • Known and/or allergy to (a component of) an investigational device.
  • Pregnant women and women with not taking adequate or currently breastfeeding.
  • of less than 12 months.
  • Any planned surgical intervention/procedure within 30 days after the study procedure.
  • Any patient considered to be hemodynamically unstable at onset of the procedure.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
209 participants (estimated)
Patient registry
No

Groups and cohorts

  • intervention

    All patients in the study will undergo same procedure. The implanted devices can be one of more of the study devices.

    Procedure: endovascular intervention

Interventions

  • Procedureendovascular intervention

    endovascular intervention

06

What researchers measure

Primary outcomes

  1. Freedeom from SAEs and SADEs (Primary Safety Endpoint)

    Freedeom from SAEs and SADEs

    Time frame: during procedure and up to 2 years after procedure

  2. Technical success rate (Primary Efficacy Endpoint)

    Technical success rate defined as ability to cross, introduce and deploy devices based on quantitative scaling by investigators

    Time frame: during procedure

Secondary outcomes

  1. General physician appraisal of the devices by means of rating scale

    General physician appraisal of the devices will be explored based on: 1. Simplicity of handling, 2. Pushability, 3. Trackability, 4. Crossability and 5. Profile

    Time frame: during procedure

  2. General physician appraisal of the devices by means of rating scale for the Luminor 18, Luminor 35, Oceanus 18 and Oceanus 35

    Physician appraisal for the Luminor 18, Luminor 35, Oceanus 18 and Oceanus 35 will be explored based on: 1. Deflation time, 2. Balloon Compliance, 3. Visibility and 4. Balloon refolding

    Time frame: during procedure

  3. General physician appraisal of the devices by means of rating scale for the Restorer, iVolution pro, iCover

    Physician appraisal for the Restorer, iVolution pro, iCover be explored based on: 1. Recoil, 2. Radial force, 3. Ease to canalize the lesion, 4. Stent coverage, 5. Stent graft recrossing and 6. Balloon refusal

    Time frame: during procedure

  4. General physician appraisal of the devices by means of rating scale for the Sergeant

    And physician appraisal for the Sergeant will be explored based on: 1. Trackability over the guide wire, 2. Absence of kinking behaviour, 3. Injection Capacity, 4. Ease of changing guide wires and 5. Ease to canalize the lesion

    Time frame: during procedure

  5. Explorative endpoint

    Freedom from SAEs and SADEs; Freedom from Target Lesion Revascularization

    Time frame: up to 2 years after procedure

07

Study locations

5 of 6 sites recruiting
  • CH Henri Duffaut
    Avignon, France
    Active, not recruiting

    Not enrolling at this site.

  • Clinique Synergia Ventoux
    Carpentras, France
    Recruiting
    • Frédéric Verdy · Contact
  • Polyclinique Inkermann
    Niort, France
    Recruiting
    • Christophe Marchand · Contact
  • L'Hôpital Privé Des Côtes D'Armor
    Plérin, France
    Recruiting
    • Jean-François Desjardins · Contact
  • Hôpital d'instruction des Armées Sainte Anne
    Toulon, France
    Recruiting
    • Fabien Beranger · Contact
  • Hôpital Privé Toulon Hyeres St. Jean
    Toulon, France
    Recruiting
    • Pierre Sarradon · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for Aug 2025, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2022
First posted
Jun 15, 2023
StartActual
Aug 1, 2023
Primary completionEst.
Aug 2025
CompletionEst.
Aug 2027
Last update
May 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05902923
Lead sponsor
iVascular S.L.U.
Responsible party
Sponsor
First posted
Jun 15, 2023
Start date
Aug 1, 2023
Primary completion
Aug 2025 (estimated)
Completion
Aug 2027 (estimated)
Last update
May 8, 2024

Study contacts

Mieke Ramsdonck
Contact
mieke.ramsdonck@fcre.eu
+32 479 64 37 60

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion